scholarly journals Long-term quality of life after surgery of head and neck cancer with microvascular reconstruction: a prospective study with 4.9-years follow-up

2019 ◽  
Vol 24 (1) ◽  
pp. 11-17 ◽  
Author(s):  
Satu Kainulainen ◽  
A. M. Koivusalo ◽  
R. P. Roine ◽  
T. Wilkman ◽  
H. Sintonen ◽  
...  

Abstract Purpose The aim of this study was to evaluate the long-term health-related quality of life (HRQoL) of head and neck cancer patients with microvascular surgery. Surgical treatment causes great changes in patient HRQoL. Studies focusing on long-term HRQoL after microvascular reconstruction for head and neck cancer patients are scarce. Methods We conducted a prospective study of 93 patients with head and neck cancer and microvascular reconstruction in Helsinki University Hospital Finland. HRQoL was measured using the 15D instrument at baseline and after a mean 4.9-years follow up. Results were compared with those of an age-standardized general population. Results Of the 93 patients, 61 (66%) were alive after follow-up; of these, 42 (69%) answered the follow-up questionnaire. The median time between surgery and HRQoL assessment was 4.9 years (range 3.7–7.8 years). The mean 15D score of all patients (n = 42) at the 4.9-years follow up was statistically significantly (p = 0.010) and clinically importantly lower than at baseline. The dimensions of “speech” and “usual activities” were significantly impaired at the end of follow up. There was a significant difference at the 4.9-years follow-up in the mean 15D score between patients and the general population (p = 0.014). After follow up, patients were significantly (p < 0.05) worse off on the dimensions of “speech,” “eating,” and “usual activities.” Conclusions Long-term HRQoL was significantly reduced in the whole patient cohort. Speech and usual activities were the most affected dimensions in head and neck cancer patients with microvascular reconstruction at the end of the 4.9-years follow up.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e17519-e17519
Author(s):  
Sachin Dhumal ◽  
Vijay Maruti Patil ◽  
Vanita Noronha ◽  
Amit Joshi ◽  
Atanu Bhattacharjee ◽  
...  

e17519 Background: NACT (neoadjuvant chemotherapy) is one of the treatment options in advanced head and neck cancer (H&N cancer); however there is limited quality of life data available in these patients. Methods: Between August 2013- April 2014, 90 technically unresectable H&N cancer patients who were underwent NACT at our centre were selected for this analysis. EORTC QLQ-C30 and HN35 version 3.0 was used for quality of life assessment at baseline and after 02 cycles of NACT. PFS and OS was estimated by Kaplan Meier method. The mean change in QOL at various domains was calculated with 95% CI. The relationship between change in QOL domain and OS was analysed. Results: The median age of the cohort was 45 years (Range 21-65 years). The predominant subsite was oral cavity, in 62 patients (68.9%).The median PFS and OS was 10.53 months (95%CI 8.1-13.0) and 20.8 months (95%CI 15.1-26.5). The mean scores for all domains of QOL are shown in table 1. Conclusions: NACT leads to improvement in QOL in patients treated with head and neck cancers and its has impact on OS.[Table: see text]


2007 ◽  
Vol 26 (6) ◽  
pp. 710-717 ◽  
Author(s):  
P. García-Peris ◽  
L. Parón ◽  
C. Velasco ◽  
C. de la Cuerda ◽  
M. Camblor ◽  
...  

2021 ◽  
Vol 161 ◽  
pp. S762-S763
Author(s):  
A. Rühle ◽  
E. Haehl ◽  
T. Kalckreuth ◽  
R. Stoian ◽  
T. Sprave ◽  
...  

Head & Neck ◽  
2001 ◽  
Vol 23 (8) ◽  
pp. 678-682 ◽  
Author(s):  
Nicolas Magné ◽  
Pierre-Yves Marcy ◽  
Emmanuel Chamorey ◽  
Emmanuel Guardiola ◽  
Xavier Pivot ◽  
...  

Author(s):  
Marie Noëlle Falewee ◽  
Christophe Hebert ◽  
Karen Benezery ◽  
Alexandre Bozec ◽  
Joël Guigay ◽  
...  

<p class="abstract"><strong>Background:</strong> Dysphagia is a serious sequel of head and neck cancer (HNC) and its treatment. This dysfunction is frequent and likely underreported by clinical exam. It seems necessary to assess its global burden during the pre, per and post treatment periods (up to 18 months), regardless of the treatment received.</p><p class="abstract"><strong>Methods:</strong> This was a prospective cohort study assessing the rate of dysphagia in first-time treated HNC patients, using the deglutition handicap index questionnaire (DHI) and the clinician reporting. Time to occurrence, severity and length of the dysfunction were recorded. The benefit of an evaluation by the patient himself was investigated.  </p><p class="abstract"><strong>Results:</strong> Of 134 evaluable patients: 22 were treated by surgery alone (16.4%), 16 by radiotherapy (RT) alone (11.9%), 3 by chemotherapy (CT) alone (2.2%), 28 by RTCT (20.9%), 31 by induction chemotherapy followed by RTCT (23.1%), 11 by surgery+RT (8.2%) and 23 by surgery+RTCT (17.2%). Patients completed 87.9% of the expected DHI. The dysphagia frequency reported was 92.2% by patient-reporting and 80.9% by clinicians-reporting, whatever the intensity. Self-perceived moderate to severe dysphagia was reported in 69.8% of patients.</p><p class="abstract"><strong>Conclusions:</strong> Given the strong impact of dysphagia on the quality of life and prognosis of HNC patients, it appears essential to perform screening and systematic monitoring. Using a simple and well accepted questionnaire, such as DHI, which is also well correlated with clinical evaluation, we demonstrated a significant frequency of dysphagia. The use of real-time patient-reported outcomes for its early detection would be an asset, particularly during long-term follow-up.</p><p class="abstract">Registered under ClinicalTrials.gov Identifier no. NCT03068559.</p>


2010 ◽  
Vol 50 (3) ◽  
pp. 390-398 ◽  
Author(s):  
Anne K. H. Aarstad ◽  
Elisabeth Beisland ◽  
Arild André Osthus ◽  
Hans J. Aarstad

Sign in / Sign up

Export Citation Format

Share Document